Fred L. Ciske

Fred L. Ciske

Auto-generated profile, based on publicly available information

Fred L. Ciske

Cayman Chem Co, 1180 East Ellsworth Rd, Ann Arbor, MI 48108 USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
KOKirk L. Olson
Kirk L. Olson
MHMelissa C. Holt
Melissa C. Holt
FCFred L. Ciske
Fred L. Ciske
JKJames B. Kramer
James B. Kramer
PHPaige E. Heiple
Paige E. Heiple
SBStephen D. Barrett
Stephen D. Barrett

15 March 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JSJohn F. Schmedtje
John F. Schmedtje
FCFred Ciske
Fred Ciske
KMKendall M. Muzzarelli
Kendall M. Muzzarelli
ZAZahra Assar
Zahra Assar
Several investigational nitric oxide donors were originally created to correct vascular endothelial dysfunction in cardiovascular diseases. These 48 compounds contain an urea-like moiety attached to the well-known NO donors isosorbide 2- and 5-mononitrate. CR-0305 and CR-0202 were synthesized and found to be nontoxic in the cell lines HMEC-1, A549/hACE2 and VeroE6. CR-0305 induced vasodilation in human coronary arteries ex vivo. Since NO can also have antiviral properties, a study of drug-protein interactions with SARS-CoV-2 was undertaken using in silico modeling. CR-0305 experimentally outperformed the other compounds, including CR-0202, in binding the catalytic site of SARS-CoV-2 papain-like protease (PLpro). PLpro is a primary target for therapeutic inhibition of SARS-CoV-2 as it mediates viral replication and modulates host innate immune responses. CR-0305 is predicted to sit firmly in the PLpro catalytic pocket as confirmed by molecular dynamics simulations, wherein stability of binding to the catalytic site of PLpro induces a conformational change in the BL2 loop to a more closed conformation as observed previously with GRL0617. Surface plasmon resonance was performed with CR-0305 and CR-0202 to characterize binding affinity to purified SARS-CoV-2 PLpro protein. CR-0305 and CR-0202 also inhibited SARS-CoV-2 infection compared to vehicle as measured by virus N protein staining with a specific antibody in A549-ACE2 and VeroE6 cells at 20 µM. CR-0305 is a coronary vasodilator that appears to bind to the catalytic site of the PLpro of SARS-CoV-2 while targeting delivery of antiviral NO to cells infected by SARS-CoV-2, suggesting multiple indications for future development.